Ostatní
Návod 
Regeneron Pharmaceuticals, Inc.
REGN
Souhrn
Výkazy
Ukazatele
Profil
Držitelé
Návštěvnost webu
Konkurence
Zprávy společnosti
Kapitalizace
68.2B
Obrat
14B
Zisk
5B
Aktiva
40B
Dluh
3B
ROE
0%
ROA
0%
PE
17
PS
5
Cena 1R
476-821
⌀ Cena
610.60
Dividenda
0.0(0.0%)
Čtvrtletní 10-Q
Celoroční 10-K
Nadcházející oznámení zisků
03-02-2026
Poslední dividenda
20-02-2026
Profil
Regeneron Pharmaceuticals, Inc. objevuje, vynalézá, vyvíjí, vyrábí a komercializuje léky pro léčbu různých nemocí po celém světě. Mezi produkty společnosti patří injekce přípravku EYLEA k léčbě makulární degenerace související s věkem ve vlhkém prostředí a diabetického makulárního edému; myopické chorioidální neovaskularizace; a diabetické retinopatie, stejně jako makulární edém po okluzi retinální žíly, včetně makulárního edému po okluzi centrální retinální žíly a makulárního edému po okluzi retinální žíly. Přípravek také poskytuje duplexní injekci pro léčbu atopické dermatitidy a astmatu u dospělých a dětí; injekci Libtaya pro léčbu metastazujícího nebo lokálně pokročilého karcinomu kožních dlaždicových buněk; prvotní injekci pro heterozygotní familiární hypercholesterolemii nebo klinické aterosklerotické kardiovaskulární onemocnění u dospělých; REGEN-COV pro covid- 19; a Kevzara roztok pro léčbu revmatoidní artritidy u dospělých. Společnost dále nabízí injekci Inmazebu k léčbě infekce způsobené Zaire ebolavirus; injekci ARCALYST k léčbě periodických syndromů spojených s kryopyrinem, včetně familiárního syndromu studeného autozánětu a syndromu muckle-wells; a injekci ZALTRAP k intravenózní infuzi k léčbě metastatického kolorektálního karcinomu; a vyvíjí produkty pro léčbu pacientů s očními, alergickými a zánětlivými, kardiovaskulárními a metabolickými, infekčními a vzácnými onemocněními; a rakovinou, bolestí a hematologickými stavy. Má dohody o spolupráci a licenci se společnostmi Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; a Kiniksa Pharmaceuticals, Ltd., a také má dohodu s Ministerstvem zdravotnictví a lidských služeb USA, jakož i se společností Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; a AstraZeneca PLC. Společnost byla založena v roce 1988 a sídlí v Tarrytownu v New Yorku.
Sektor
Healthcare
Odvětví
Biotechnology
Počet zaměstnanců
15158
Založení
1991-04-02
Podobné společnosti
$ 260.66
- $ 3.93
$ 305.00
- $ 12.78
$ 447.69
+ $ 4.99
$ 119.67
- $ 0.57
$ 863.20
+ $ 8.55
$ 29.05
+ $ 0.39
$ 700.73
- $ 7.72
Zahraniční články
Výsledovka
Rozvaha
Peněžní toky
Výsledovka
Výsledovka
Rozvaha
Peněžní toky
V miliardách (USD)
| Revenue | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenues | 14.34 | 14.34 | 14.20 | 13.12 | 12.17 | 16.07 | 8.50 | 7.86 | 6.71 | 5.87 | 4.86 | 4.10 | 2.82 | 2.10 | 1.38 | 0.45 | 0.46 | |
| Cost of Revenues | 2.10 | 2.10 | 1.97 | 1.82 | 1.56 | 2.44 | 1.12 | 0.78 | 0.43 | 0.40 | 0.30 | 0.39 | 0.21 | 0.16 | 0.08 | 0.00 | 0.00 | |
| Gross Profit | 12.24 | 12.24 | 12.23 | 11.30 | 10.61 | 13.63 | 7.38 | 7.08 | 6.28 | 5.48 | 4.56 | 3.71 | 2.61 | 1.95 | 1.29 | 0.44 | 0.46 |
| Revenue | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenues | 3.88 | 3.75 | 3.68 | 3.03 | 3.79 | 3.72 | 3.55 | 3.15 | 3.43 | 3.36 | |
| Cost of Revenues | 0.58 | 0.52 | 0.53 | 0.46 | 0.57 | 0.49 | 0.48 | 0.43 | 0.52 | 0.21 | |
| Gross Profit | 3.30 | 3.23 | 3.15 | 2.56 | 3.22 | 3.23 | 3.07 | 2.71 | 2.92 | 3.15 |
| Operating Income | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| R&D Expenses | 0.00 | 0.00 | 0.00 | 4.44 | 3.59 | 2.91 | 2.74 | 3.04 | 2.19 | 2.08 | 2.05 | 1.62 | 1.27 | 0.86 | 0.63 | 0.53 | 0.49 | |
| Selling General & Admin Expenses | 0.00 | 0.00 | 0.00 | 2.63 | 2.12 | 1.82 | 1.35 | 1.83 | 1.56 | 1.32 | 1.18 | 0.84 | 0.50 | 0.33 | 0.21 | 0.12 | 0.07 | |
| Depreciation & Amortization | 0.54 | 0.54 | 0.48 | 0.42 | 0.43 | 0.44 | 0.29 | 0.21 | 0.15 | 0.15 | 0.10 | 0.07 | 0.05 | 0.04 | 0.04 | 0.03 | 0.02 | |
| Total Operating Expenses | 8.66 | 8.66 | 8.24 | 7.25 | 5.62 | 4.69 | 3.80 | 4.87 | 3.74 | 3.40 | 3.23 | 2.46 | 1.78 | 1.19 | 0.84 | 0.65 | 0.55 | |
| Operating Income | 3.58 | 3.58 | 3.99 | 4.05 | 4.74 | 8.95 | 3.58 | 2.21 | 2.53 | 2.08 | 1.33 | 1.25 | 0.84 | 0.76 | 0.46 | -0.21 | -0.10 |
| Operating Income | TTM | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| R&D Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.18 | 1.08 | ||
| Selling General & Admin Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.74 | 0.64 | ||
| Depreciation & Amortization | 0.15 | 0.14 | 0.14 | 0.13 | 0.13 | 0.12 | 0.12 | 0.11 | 0.11 | 0.11 | ||
| Total Operating Expenses | 2.42 | 2.21 | 2.07 | 1.97 | 2.23 | 2.05 | 2.00 | 1.96 | 1.91 | 1.72 | ||
| Operating Income | 0.88 | 1.03 | 1.08 | 0.59 | 0.99 | 1.18 | 1.07 | 0.75 | 0.97 | 1.11 |
| Net Income | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Interest Income | 0.72 | 0.72 | 0.71 | 0.50 | 0.16 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Interest Expense | 0.04 | 0.04 | 0.06 | 0.07 | 0.06 | 0.06 | 0.06 | 0.03 | 0.03 | 0.03 | 0.01 | 0.01 | 0.04 | 0.05 | 0.05 | 0.02 | 0.01 | |
| Other Expense | 1.65 | 1.65 | 0.79 | 0.15 | 0.12 | 0.38 | 0.23 | 0.22 | 0.02 | 0.00 | 0.00 | -0.01 | -0.03 | 0.00 | 0.00 | 0.00 | 0.00 | |
| IBT | 5.23 | 5.23 | 4.78 | 4.20 | 4.86 | 9.33 | 3.81 | 2.43 | 2.55 | 2.08 | 1.33 | 1.23 | 0.78 | 0.71 | 0.41 | -0.22 | -0.10 | |
| Income Tax Expense | 0.73 | 0.73 | 0.37 | 0.25 | 0.52 | 1.25 | 0.30 | 0.31 | 0.11 | 0.88 | 0.43 | 0.59 | 0.43 | 0.29 | -0.34 | 0.00 | 0.00 | |
| Net Income | 4.50 | 4.50 | 4.41 | 3.95 | 4.34 | 8.08 | 3.51 | 2.12 | 2.44 | 1.20 | 0.90 | 0.64 | 0.35 | 0.42 | 0.75 | -0.22 | -0.10 |
| Net Income | TTM | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Interest Income | 0.19 | 0.18 | 0.17 | 0.17 | 0.18 | 0.19 | 0.18 | 0.16 | 0.15 | 0.13 | ||
| Interest Expense | 0.01 | 0.02 | 0.00 | 0.01 | 0.01 | 0.01 | 0.01 | 0.02 | 0.02 | 0.02 | ||
| Other Expense | 0.16 | 0.74 | 0.44 | 0.31 | -0.03 | 0.31 | 0.56 | -0.05 | 0.17 | 0.00 | ||
| IBT | 1.04 | 1.76 | 1.52 | 0.91 | 0.96 | 1.49 | 1.63 | 0.70 | 1.15 | 1.11 | ||
| Income Tax Expense | 0.20 | 0.30 | 0.13 | 0.10 | 0.04 | 0.15 | 0.20 | -0.02 | -0.01 | 0.10 | ||
| Net Income | 0.84 | 1.46 | 1.39 | 0.81 | 0.92 | 1.34 | 1.43 | 0.72 | 1.16 | 1.01 |
| Per Share Data | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EPS | $0.00 | $0.00 | $0.00 | $37.05 | $40.51 | $76.40 | $32.65 | $19.38 | $21.29 | $11.27 | $8.55 | $6.17 | $3.36 | $4.23 | $7.92 | $-2.45 | $-1.26 | |
| EPS Diluted | $0.00 | $0.00 | $0.00 | $34.77 | $38.22 | $71.97 | $30.52 | $18.46 | $21.29 | $10.34 | $7.70 | $5.52 | $2.98 | $3.72 | $6.75 | $-2.45 | $-1.26 | |
| Shares Outstanding | 0.10 | 0.10 | 0.11 | 0.11 | 0.11 | 0.11 | 0.12 | 0.11 | 0.11 | 0.12 | 0.12 | 0.12 | 0.11 | 0.11 | 0.11 | 0.09 | 0.08 | |
| Diluted Shares Outstanding | 0.11 | 0.11 | 0.12 | 0.11 | 0.11 | 0.11 | 0.12 | 0.11 | 0.11 | 0.12 | 0.12 | 0.12 | 0.11 | 0.11 | 0.12 | 0.09 | 0.08 |
| Per Share Data | TTM | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EPS | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $10.88 | $9.48 | ||
| EPS Diluted | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $10.19 | $8.89 | ||
| Shares Outstanding | 0.10 | 0.10 | 0.11 | 0.11 | 0.11 | 0.11 | 0.11 | 0.11 | 0.11 | 0.11 | ||
| Diluted Shares Outstanding | 0.11 | 0.11 | 0.11 | 0.11 | 0.11 | 0.12 | 0.12 | 0.12 | 0.11 | 0.11 |
| Current Assets | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash And Equivalents | 1.93 | 2.49 | 2.73 | 3.11 | 2.89 | 2.19 | 1.62 | 1.47 | 0.81 | 0.54 | 0.81 | 0.65 | 0.54 | 0.23 | 0.48 | 0.11 | |
| Short Term Investments | 7.89 | 6.52 | 8.11 | 4.64 | 2.81 | 1.39 | 1.60 | 1.34 | 0.60 | 0.50 | 0.24 | 0.25 | 0.16 | 0.08 | 0.04 | 0.14 | |
| Total Cash & ST Investments | 9.82 | 9.01 | 10.84 | 14.33 | 12.53 | 6.72 | 6.47 | 4.56 | 2.90 | 1.90 | 1.68 | 1.36 | 1.08 | 0.59 | 0.53 | 0.63 | |
| Accounts Receivable | 5.72 | 6.21 | 5.67 | 5.33 | 6.04 | 4.11 | 2.67 | 2.24 | 1.97 | 1.61 | 1.47 | 1.02 | 0.89 | 0.69 | 0.10 | 0.09 | |
| Inventory | 2.87 | 3.09 | 2.58 | 2.40 | 1.95 | 1.92 | 1.42 | 1.15 | 0.73 | 0.40 | 0.24 | 0.13 | 0.07 | 0.03 | 0.01 | -0.02 | |
| Other Current Assets | 0.67 | 0.35 | 0.39 | 0.93 | 0.33 | 1.16 | 0.96 | 0.24 | 0.22 | 0.13 | 0.16 | 0.12 | 0.14 | 0.18 | 0.81 | 0.02 | |
| Total Current Assets | 19.08 | 18.66 | 19.48 | 22.06 | 20.52 | 12.75 | 10.56 | 7.96 | 5.60 | 3.91 | 3.38 | 2.51 | 2.25 | 1.62 | 0.91 | 0.72 |
| Current Assets | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash And Equivalents | 2.51 | 2.00 | 3.09 | 2.49 | 2.01 | 1.92 | 2.60 | 2.73 | 2.15 | 1.94 | |
| Short Term Investments | 5.94 | 5.47 | 5.26 | 6.52 | 7.78 | 7.89 | 7.92 | 8.11 | 7.76 | 6.99 | |
| Total Cash & ST Investments | 8.44 | 7.47 | 8.35 | 9.01 | 9.80 | 9.81 | 10.52 | 10.84 | 9.91 | 8.93 | |
| Accounts Receivable | 5.69 | 5.61 | 5.56 | 6.21 | 6.11 | 5.72 | 5.22 | 5.67 | 5.58 | 5.12 | |
| Inventory | 3.25 | 3.21 | 3.19 | 3.09 | 3.02 | 2.87 | 2.71 | 2.58 | 2.56 | 2.01 | |
| Other Current Assets | 0.60 | 0.57 | 0.47 | 0.35 | 0.41 | 0.68 | 0.41 | 0.39 | 0.57 | 0.37 | |
| Total Current Assets | 17.98 | 16.86 | 17.57 | 18.66 | 19.33 | 19.08 | 18.87 | 19.48 | 18.63 | 16.92 |
| Long-Term Assets | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Property, Plant & Equipment | 4.31 | 4.60 | 4.22 | 3.76 | 3.48 | 3.22 | 2.89 | 2.58 | 2.36 | 2.08 | 1.59 | 0.97 | 0.53 | 0.38 | 0.37 | 0.35 | |
| Goodwill | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Intangible Assets | 1.10 | 1.15 | 1.04 | 0.92 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Long-Term Investments | 7.92 | 8.90 | 5.40 | 5.41 | 6.84 | 3.14 | 3.26 | 1.76 | 1.49 | 0.86 | 0.63 | 0.46 | 0.39 | 0.27 | 0.28 | 0.37 | |
| Other Long-Term Assets | 0.80 | 1.14 | 0.37 | -4.66 | 0.56 | 0.33 | 0.53 | 0.37 | 0.30 | 0.15 | 0.17 | 0.07 | 0.17 | 0.08 | -0.23 | -0.35 | |
| Total Long-Term Assets | 17.01 | 19.10 | 13.60 | 7.15 | 4.91 | 4.41 | 4.25 | 3.78 | 3.17 | 3.06 | 2.23 | 1.36 | 0.70 | 0.46 | 0.41 | 0.37 | |
| Total Assets | 36.09 | 37.76 | 33.08 | 29.21 | 25.43 | 17.16 | 14.81 | 11.73 | 8.76 | 6.97 | 5.61 | 3.87 | 2.95 | 2.08 | 1.32 | 1.09 |
| Long-Term Assets | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Property, Plant & Equipment | 5.00 | 4.84 | 4.69 | 4.60 | 4.44 | 4.31 | 4.23 | 4.15 | 4.01 | 3.92 | |
| Goodwill | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Intangible Assets | 1.38 | 1.35 | 1.17 | 1.15 | 1.12 | 1.10 | 1.06 | 1.04 | 1.02 | 0.95 | |
| Long-Term Investments | 10.29 | 10.06 | 9.28 | 8.90 | 8.49 | 7.72 | 6.98 | 5.40 | 5.78 | 6.33 | |
| Other Long-Term Assets | 1.67 | 1.54 | 1.39 | 1.14 | 1.04 | 0.99 | 0.47 | 0.44 | 0.41 | 0.39 | |
| Total Long-Term Assets | 22.19 | 21.36 | 19.97 | 19.10 | 18.11 | 17.01 | 15.50 | 13.60 | 13.53 | 13.73 | |
| Total Assets | 40.17 | 38.22 | 37.55 | 37.76 | 37.44 | 36.09 | 34.37 | 33.08 | 32.16 | 30.66 |
| Current Liabilities | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Accounts Payable | 0.56 | 0.79 | 0.61 | 0.59 | 0.56 | 0.48 | 0.42 | 0.22 | 0.18 | 0.13 | 0.14 | 0.10 | 0.06 | 0.04 | 0.03 | -0.05 | |
| Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.72 | 0.72 | 1.63 | 0.00 | -0.09 | 0.47 | 0.13 | 0.45 | 0.35 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Other Current Liabilities | 2.36 | 2.31 | 2.36 | 1.99 | 1.73 | 0.12 | 0.78 | 0.77 | 0.00 | 0.49 | 0.01 | 0.10 | 0.15 | 0.03 | 0.07 | 0.05 | |
| Current Liabilities | 3.51 | 3.94 | 3.42 | 3.85 | 3.45 | 2.81 | 1.79 | 1.35 | 0.97 | 0.98 | 0.76 | 0.62 | 0.26 | 0.12 | 0.40 | 0.06 |
| Current Liabilities | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Accounts Payable | 0.90 | 0.72 | 0.71 | 0.79 | 0.50 | 0.56 | 0.67 | 0.61 | 0.54 | 0.55 | |
| Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Other Current Liabilities | 2.98 | 2.46 | 2.24 | 2.31 | 2.54 | 2.36 | 2.39 | 2.36 | 2.64 | 2.18 | |
| Current Liabilities | 4.43 | 3.67 | 3.57 | 3.94 | 3.66 | 3.51 | 3.58 | 3.42 | 3.60 | 3.10 |
| Long-Term Liabilities | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Long-Term Debt | 1.98 | 2.70 | 2.70 | 2.70 | 2.70 | 2.70 | 0.71 | 0.71 | 0.70 | 0.48 | 0.38 | 0.46 | 0.51 | 0.46 | 0.44 | 0.16 | |
| Capital Leases | 0.72 | 0.72 | 0.72 | 0.72 | 0.72 | 0.72 | 0.71 | 0.71 | 0.70 | 0.48 | 0.36 | 0.31 | 0.19 | 0.16 | 0.16 | 0.16 | |
| Def. Tax Liability | 0.72 | 0.00 | 0.00 | 0.00 | -0.68 | -0.69 | -0.29 | -0.50 | -0.15 | -0.10 | -0.12 | -0.04 | -0.01 | -0.01 | -0.26 | -0.01 | |
| Total Liabilities | 7.88 | 8.41 | 7.11 | 6.55 | 6.67 | 6.14 | 3.72 | 2.98 | 2.62 | 2.52 | 1.95 | 1.33 | 1.00 | 0.84 | 0.84 | 0.56 |
| Long-Term Liabilities | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Long-Term Debt | 2.71 | 2.71 | 2.70 | 2.70 | 2.70 | 2.70 | 2.70 | 2.70 | 2.70 | 2.70 | |
| Capital Leases | 0.72 | 0.72 | 0.72 | 0.72 | 0.72 | 0.72 | 0.72 | 0.72 | 0.72 | 0.72 | |
| Def. Tax Liability | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.05 | 0.00 | 0.00 | |
| Total Liabilities | 9.21 | 8.28 | 8.16 | 8.41 | 8.12 | 7.88 | 7.38 | 7.11 | 7.26 | 6.64 |
| Total Common Equity | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Retained Earnings | 29.41 | 31.67 | 27.26 | 23.31 | 18.97 | 10.89 | 7.38 | 5.25 | 2.95 | 1.75 | 0.85 | 0.26 | -0.09 | -0.52 | -1.27 | -1.05 | |
| Comprehensive Income | -0.07 | -0.01 | -0.08 | -0.24 | -0.03 | 0.03 | 0.02 | -0.01 | 0.00 | -0.01 | 0.01 | 0.05 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Total Common Equity | 28.21 | 29.35 | 25.97 | 22.66 | 18.77 | 11.03 | 11.09 | 8.76 | 6.14 | 4.45 | 3.65 | 2.54 | 1.95 | 1.25 | 0.49 | 0.53 |
| Total Common Equity | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Retained Earnings | 35.05 | 33.68 | 32.38 | 31.67 | 30.76 | 29.41 | 27.98 | 27.26 | 26.10 | 25.09 | |
| Comprehensive Income | 0.07 | 0.05 | 0.03 | -0.01 | 0.06 | -0.07 | -0.08 | -0.08 | -0.18 | -0.20 | |
| Total Common Equity | 30.96 | 29.94 | 29.39 | 29.35 | 29.33 | 28.21 | 26.99 | 25.97 | 24.90 | 24.02 |
| Other | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Debt | 2.70 | 2.70 | 2.70 | 2.70 | 2.70 | 2.70 | 0.71 | 0.71 | 0.70 | 0.48 | 0.38 | 0.46 | 0.51 | 0.46 | 0.44 | 0.16 | |
| Book Value | 28.21 | 29.35 | 25.97 | 22.66 | 18.77 | 11.03 | 11.09 | 8.76 | 6.14 | 4.45 | 3.65 | 2.54 | 1.95 | 1.25 | 0.49 | 0.53 |
| Other | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Book Value | 30.96 | 29.94 | 29.39 | 29.35 | 29.33 | 28.21 | 26.99 | 25.97 | 24.90 | 24.02 |
| Cash Flow From Operating Activities | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | 4.32 | 4.50 | 4.41 | 3.95 | 4.34 | 8.08 | 3.51 | 2.12 | 2.44 | 1.20 | 0.90 | 0.64 | 0.35 | 0.42 | 0.75 | -0.22 | -0.10 | |
| Depreciation & Amortization | 0.45 | 0.54 | 0.48 | 0.42 | 0.34 | 0.29 | 0.24 | 0.21 | 0.15 | 0.15 | 0.10 | 0.07 | 0.05 | 0.04 | 0.04 | 0.03 | 0.02 | |
| Stock-Based Compensation | 0.90 | 0.99 | 0.98 | 0.89 | 0.73 | 0.60 | 0.43 | 0.46 | 0.43 | 0.51 | 0.56 | 0.46 | 0.31 | 0.20 | 0.09 | 0.06 | 0.04 | |
| Change Working Capital | -0.72 | 0.53 | -0.62 | -0.09 | -0.24 | -1.92 | -1.50 | -0.20 | -0.70 | -0.93 | 0.23 | 0.23 | 0.02 | -0.19 | -0.67 | -0.02 | 0.14 | |
| Change In Accounts Receivable | -0.59 | 0.50 | -0.55 | -0.34 | 0.71 | -1.93 | -1.36 | -0.47 | -0.27 | -0.36 | -0.14 | -0.49 | -0.06 | -0.20 | -0.59 | -0.02 | -0.03 | |
| Change In Accounts Payable | 0.64 | 0.74 | 0.74 | 0.60 | -0.14 | 0.87 | 0.12 | 0.44 | 0.21 | -0.02 | 0.25 | 0.30 | 0.16 | 0.14 | 0.01 | 0.00 | 0.00 | |
| Change In Inventories | -0.46 | -0.28 | -0.62 | -0.27 | -0.70 | -0.49 | -0.53 | -0.34 | -0.39 | -0.31 | -0.15 | -0.11 | -0.06 | -0.05 | -0.05 | 0.00 | 0.00 | |
| Other Non-cash Items | 0.83 | -0.81 | -0.08 | 0.27 | 0.60 | -1.28 | -1.13 | 0.10 | -0.40 | -0.04 | 0.49 | 0.62 | 0.36 | 0.13 | -0.86 | 0.01 | 0.00 | |
| Cash from Operations | 4.07 | 0.00 | 0.00 | 4.59 | 5.01 | 7.08 | 2.62 | 2.43 | 2.20 | 1.31 | 1.49 | 1.33 | 0.75 | 0.59 | -0.07 | -0.14 | 0.10 |
| Cash Flow From Operating Activities | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | 0.84 | 1.46 | 1.39 | 0.81 | 0.92 | 1.34 | 1.43 | 0.72 | 1.16 | 1.01 | |
| Depreciation & Amortization | 0.00 | 0.14 | 0.14 | 0.13 | 0.13 | 0.12 | 0.12 | 0.11 | 0.11 | 0.11 | |
| Stock-Based Compensation | 0.25 | 0.24 | 0.25 | 0.26 | 0.30 | 0.23 | 0.22 | 0.23 | 0.24 | 0.20 | |
| Change Working Capital | 0.01 | 0.63 | -0.23 | 0.13 | -0.09 | 0.47 | -0.91 | 0.44 | -0.06 | -0.19 | |
| Change In Accounts Receivable | -0.05 | -0.08 | -0.03 | 0.66 | -0.12 | -0.39 | -0.49 | 0.45 | -0.08 | -0.46 | |
| Change In Accounts Payable | -0.02 | 0.76 | 0.22 | -0.21 | 0.23 | 0.19 | 0.20 | 0.11 | 0.03 | 0.30 | |
| Change In Inventories | 0.00 | -0.08 | -0.04 | -0.15 | -0.12 | -0.16 | -0.18 | -0.16 | -0.05 | -0.08 | |
| Other Non-cash Items | 0.07 | -0.56 | -0.27 | -0.14 | 0.28 | -0.70 | -0.40 | 0.20 | -0.08 | 0.12 | |
| Cash from Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.09 | 1.11 |
| Cash Flow From Investing Activities | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Capital Expenditure | -0.86 | -0.90 | -0.76 | 0.00 | -0.59 | -0.55 | -0.61 | -0.43 | -0.38 | -0.27 | -0.51 | -0.68 | -0.33 | -0.16 | -0.05 | -0.06 | -0.10 | |
| Acquisitions | 0.21 | 0.00 | -0.02 | -0.05 | -0.23 | 0.55 | 0.61 | 0.43 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Investments | -15.45 | -10.96 | -16.62 | -11.65 | -7.49 | -7.05 | -3.24 | -3.20 | -1.85 | -1.28 | -0.81 | -0.56 | -0.56 | -0.58 | -0.47 | -0.24 | -0.61 | |
| Sales of Investment | 13.57 | 11.55 | 15.03 | 9.44 | 5.55 | 2.22 | 3.79 | 1.60 | 0.78 | 0.54 | 0.27 | 0.33 | 0.48 | 0.38 | 0.44 | 0.43 | 0.28 | |
| Other Investing Activities | -2.01 | 0.00 | 0.00 | -0.93 | -1.03 | -4.83 | 0.54 | -1.60 | -1.08 | -0.73 | -0.53 | -0.23 | -0.09 | -0.20 | -0.03 | 0.00 | 0.00 | |
| Cash from Investing | -2.81 | 0.00 | 0.00 | -3.19 | -3.78 | -5.38 | -0.07 | -2.03 | -1.46 | -1.01 | -1.05 | -0.91 | -0.42 | -0.36 | -0.08 | 0.13 | -0.43 |
| Cash Flow From Investing Activities | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Capital Expenditure | -0.29 | -0.20 | -0.22 | -0.23 | -0.27 | -0.18 | -0.21 | -0.16 | -0.31 | -0.18 | |
| Acquisitions | 0.00 | 0.00 | 0.00 | 0.00 | -0.01 | -0.02 | 0.02 | 0.00 | 0.00 | 0.20 | |
| Investments | -2.04 | -3.52 | -2.86 | -2.54 | -1.95 | -4.59 | -4.42 | -5.66 | -2.13 | -3.24 | |
| Sales of Investment | 2.56 | 3.37 | 2.17 | 3.46 | 2.58 | 4.26 | 4.05 | 4.13 | 2.38 | 3.00 | |
| Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.19 | -0.27 | |
| Cash from Investing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -0.07 | -0.50 |
| Cash Flow From Financing Activities | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt Repaid | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -1.50 | 0.00 | 0.00 | -0.02 | -0.04 | -0.17 | -0.22 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Debt Issued | 0.00 | 2.70 | 0.00 | 0.00 | 0.00 | 0.00 | 3.48 | 0.01 | 0.01 | 0.24 | 0.15 | 0.08 | 0.18 | 0.05 | 0.02 | 0.28 | 0.16 | |
| Issuance of Common Stock | 1.69 | 0.00 | 0.00 | 1.15 | 1.52 | 1.67 | 2.58 | 0.21 | 0.11 | 0.24 | 0.13 | 0.21 | 0.13 | 0.06 | 0.06 | 0.02 | 0.20 | |
| Repurchase of Common Stock | -2.32 | -3.44 | -3.63 | -2.94 | -2.53 | -2.68 | -6.53 | -0.46 | -0.19 | -0.30 | -0.14 | -0.16 | -0.27 | -0.20 | -0.16 | 0.00 | 0.00 | |
| Dividends Paid | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -0.36 | -0.50 | -0.55 | -0.29 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Other Financing Activities | -1.24 | 0.00 | 0.00 | -0.70 | 0.00 | 0.00 | 3.48 | 0.00 | 0.00 | 0.42 | -0.14 | 0.41 | 0.45 | 0.22 | 0.00 | 0.37 | 0.05 | |
| Cash from Financing | -1.28 | 0.00 | 0.00 | -1.79 | -1.01 | -1.01 | -1.97 | -0.25 | -0.08 | -0.02 | -0.70 | -0.26 | -0.21 | 0.08 | -0.10 | 0.38 | 0.24 |
| Cash Flow From Financing Activities | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt Repaid | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Debt Issued | 2.71 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Issuance of Common Stock | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.30 | 0.27 | |
| Repurchase of Common Stock | -0.67 | -0.66 | -1.06 | -1.05 | -1.23 | -0.74 | -0.92 | -0.29 | -0.75 | -0.68 | |
| Dividends Paid | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Other Financing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -0.46 | -0.13 | |
| Cash from Financing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -0.45 | -0.41 |
| Cash position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Change in Cash | -0.01 | 0.63 | -0.25 | -0.38 | 0.22 | 0.69 | 0.58 | 0.15 | 0.66 | 0.28 | -0.27 | 0.16 | 0.11 | 0.31 | -0.25 | 0.37 | -0.09 | |
| Closing Cash Balance | 1.93 | 3.12 | 2.49 | 2.74 | 3.12 | 2.90 | 2.21 | 1.63 | 1.48 | 0.81 | 0.54 | 0.81 | 0.65 | 0.54 | 0.23 | 0.48 | 0.11 |
| Cash position | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Change in Cash | 0.61 | 0.50 | -1.08 | 0.60 | 0.48 | 0.08 | -0.68 | -0.13 | 0.58 | 0.21 | |
| Closing Cash Balance | 3.12 | 2.51 | 2.02 | 3.09 | 2.49 | 2.01 | 1.93 | 2.60 | 2.74 | 2.16 |
| Free Cash Flow | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 3.21 | 4.08 | 3.66 | 3.67 | 4.42 | 6.53 | 2.00 | 2.00 | 1.81 | 1.03 | 0.97 | 0.65 | 0.42 | 0.43 | -0.12 | -0.20 | 0.00 | |
| Real Free Cash Flow | 2.31 | 3.09 | 2.68 | 2.78 | 3.70 | 5.93 | 1.57 | 1.54 | 1.38 | 0.53 | 0.41 | 0.19 | 0.11 | 0.23 | -0.22 | -0.25 | -0.04 |
| Free Cash Flow | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 0.92 | 1.42 | 0.97 | 0.77 | 1.00 | 1.11 | 0.14 | 1.35 | 0.78 | 0.94 | |
| Real Free Cash Flow | 0.67 | 1.18 | 0.72 | 0.52 | 0.69 | 0.88 | -0.08 | 1.12 | 0.54 | 0.73 |
Nacenění
Finance
Efektivita
Marže
Dividenda
Ostatní
Nacenění
| Ukazatel | Aktuální | Historické | Konkurence |
|---|---|---|---|
| P/E | 17.5 | 20.7 | -1.4 |
| P/S | 5.5 | 10.2 | 9.4 |
| P/B | 2.5 | 9.4 | 5.2 |
| P/FCF | 25.5 | 45.5 | -1.5 |
| Market cap | $68.2 | $71.1 |
P/E (Price to Earnings Ratio) – Poměr ceny akcie k zisku za posledních 12 měsíců. Říká, kolik korun investor zaplatí za 1 korunu zisku. Např.: P/E = 15 znamená, že pokud akcie stojí 15 Kč, firma vydělala 1 Kč za poslední rok.
Finance
| Ukazatel | Aktuální | Historické | Srovnání |
|---|---|---|---|
| Debt to Assets | 0 % | 11.9 % | 0 % |
| Debt to Income | 60.1 % | -0.2 % | 0 % |
| Debt to Free cash flow | 87.6 % | 72.3 % | 0 % |
| Interest expense percentage | 1.2 % | 10.2 % | 44.7 % |
| Current ratio | 4.1 | 5.2 | 0 |
Efektivita
| Ukazatel | Aktuální | Historické | Srovnání |
|---|---|---|---|
| ROE | 14.6 % | 16.2 % | 0 % |
| ROA | 11.2 % | 12.3 % | 0 % |
| CapEx to Revenue | 6.6 % | 8.7 % | 0 % |
| RaD to Revenue | 0 % | 45.7 % | 0 % |
| ROEM | 949,483.6 | 715983.8 |
Marže
| Ukazatel | Aktuální | Historické | Srovnání |
|---|---|---|---|
| Gross margin | 85.4 % | 91.2 % | 68.7 % |
| Operating margin | 24.9 % | 25.1 % | 35.5 % |
| Net margin | 31.4 % | 20.9 % | 9.5 % |
Dividenda
| Ukazatel | Aktuální | Historické | Srovnání |
|---|---|---|---|
| Dividend yield | 0 % | 0.3 % | 0 % |
| Dividend payout percentage | 0 % | 15.4 % | 0 % |
Dividend yield (Dividendový výnos) ukazuje aktuální procentuální výnos z dividend vůči ceně akcie.
Ostatní
| Ukazatel | Aktuální | Historické |
|---|---|---|
| Shares outstanding | 107.5 mil | 110.5 mil |
| Employee count | 15.1 tis | 3.8 tis |
Placený obsah
Pro přístup na tuto stránku budete potřebovat placené členství.
Vyzkoušejte placený obsah na akciích: Apple Inc. nebo CEZ, a. s.
Placený obsah
Pro přístup na tuto stránku budete potřebovat placené členství.
Vyzkoušejte placený obsah na akciích: Apple Inc. nebo CEZ, a. s.
Placený obsah
Pro přístup na tuto stránku budete potřebovat placené členství.
Vyzkoušejte placený obsah na akciích: Apple Inc. nebo CEZ, a. s.
Placený obsah
Pro přístup na tuto stránku budete potřebovat placené členství.
Vyzkoušejte placený obsah na akciích: Apple Inc. nebo CEZ, a. s.
Placený obsah
Pro přístup na tuto stránku budete potřebovat placené členství.
Vyzkoušejte placený obsah na akciích: Apple Inc. nebo CEZ, a. s.
